YD BIO LTD
YDESNASDAQTrading Snapshot
- Day Range
- $5.86 – $6.60
- 52-Week Range
- $1.70 – $17.37
- Volume (shares)
- 96,182
- Avg Volume (shares)
- —
- Shares Outstanding
- 70.8M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $596,817
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.03
- Dividend Yield
- —
- Dilution (1yr)
- −15.5%
YD BIO LTD
YDES
StockOtter · stockotter.spaceAbout YD BIO LTD
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
YD Bio (NASDAQ:YDES) Stock Crosses Above 200-Day Moving Average – Here’s What Happened
YD Bio Limited (NASDAQ: YDES - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $5.68 and traded as high as $6.15. YD Bio shares
YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs
TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic
YD Bio Limited (NASDAQ:YDES) Sees Significant Increase in Short Interest
YD Bio Limited (NASDAQ: YDES - Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 177,332 shares, a growth of 312.8%
YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and oph
YD Bio (NASDAQ:YDES) Shares Down 4.4% – Here’s Why
YD Bio Limited (NASDAQ: YDES - Get Free Report)'s share price dropped 4.4% during mid-day trading on Wednesday. The stock traded as low as $6.80 and last traded at $7.2760. 68,234 shares changed hands during mid-day trad
YD Bio Limited (NASDAQ:YDES) Sees Large Increase in Short Interest
YD Bio Limited (NASDAQ: YDES - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 42,960 shares, an increase of 223.2%